Yumanity Therapeutics, Inc.

NasdaqCM:YMTX Stock Report

Market Cap: US$143.6m

Yumanity Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Yumanity Therapeutics.

Key information


Earnings growth rate


EPS growth rate

Biotechs earnings growth23.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage


Last updatedn/a

Recent future growth updates

No updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Yumanity Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:YMTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if YMTX's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if YMTX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if YMTX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if YMTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if YMTX's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if YMTX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.